A Phase 1 interventional study of Dinutuximab beta and chemotherapy treatment called GPOH in Neuroblastoma, sponsored by Princess Maxima Center for Pediatric Oncology. Recruiting at 1 site in Netherlands. Open to participants aged 18 Months to 18 Years. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Princess Maxima Center for Pediatric Oncology · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 23 studies in Neuroblastoma with a site in Netherlands — 5 open to participants now, 6 under way, 1 of them phase 3. Neuroblastoma · Netherlands.
Among the 23 studies in Neuroblastoma with a site in Netherlands, this one is the 17th largest by planned enrollment of the 21 interventional ones that give a count, is one of 2 that started in 2025, is one of 5 in phase 1, and was the 22nd registered.
676 studies on the registry are indexed under Neuroblastoma; 127 are open to participants now.
Browse Neuroblastoma studies →5 of the 23 studies in Neuroblastoma with a site in Netherlands are open now. Recruiting first, the newest first:
Princess Maxima Center for Pediatric Oncology · Sites in Netherlands
Ages 1–18
Merck Sharp & Dohme LLC · Sites in Netherlands, United States, Australia and 20 more countries
Ages 6 mo–25 yrs
Jakob Stenman · Sites in Netherlands, Denmark, Lithuania and 4 more countries
Ages 18 mo+
Gustave Roussy, Cancer Campus, Grand Paris · Sites in Netherlands, Australia, Austria and 17 more countries
Ages up to 21
A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →
Of the 104 Neuroblastoma studies recruiting now, 25 (24%) set no upper age limit and 74 (71%) stop at 75 or younger; 101 take children under 18; 3 take healthy volunteers.
This study: 18 Months to 18 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
23 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 9 · Phase 2 11 · Phase 3 5 · Phase 4 1
First in 1988; this study’s year is marked. 2 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 38 is above the median of 33 across 508 interventional studies indexed under Neuroblastoma.
Median enrollment 115 across the 21 interventional studies, 10,000 across the 1 observational. Of the 16 that completed or were terminated, 4 (25%) have results posted.
This tab as a report to print or save as PDF → With an account.
8 of 23 have an industry lead sponsor. The 10 most frequent:
Princess Maxima Center for Pediatric Oncology is the lead sponsor of 15 studies on the registry; 13 are open to participants now.
Princess Maxima Center for Pediatric Oncology has 2 studies filed under Neuroblastoma — fewer than ten, so there is no comparison to draw.
3 of the studies in Neuroblastoma with a site in Netherlands that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04221035Phase 3Gustave Roussy, Cancer Campus, Grand ParisHigh-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) | 2026-11 |
| NCT03975829Novartis PharmaceuticalsPediatric Long-Term Follow-up and Rollover Study | 2026-11-24 |
| NCT07399821Princess Maxima Center for Pediatric OncologyAn Imaging Study of Anti-GD2-800CW in Patients With Neuroblastoma | 2027-04-01 |
Add all 3 to your calendar (.ics) → With an account.
Among the 23 studies in Neuroblastoma with a site in Netherlands, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this clinical trial is to to assess the dose level of dinutuximab Beta (DB) when combined with 2 different induction chemotherapy regimens (named GPOH or rapid COJEC) in newly diagnosed high-risk neuroblastoma patients. The main question is:
Participants will receive:
This study is a multicenter, open-label, dual-cohort, Phase 1 study of DB combined with each of 2 different induction chemotherapy regimens in 2 cohorts. When the recommended cumulative DB dose level has been defined for each of the chemotherapy regimens, a confirmation cohort of 10 evaluable patients per cohort will be enrolled. The maximum number of patients to be enrolled in the dose escalation and dose confirmation parts of the study combined will be 38 evaluable patients for both induction chemotherapy regimens.
For each patient, there will be a screening period of up to 21 days, a treatment period consisting of approximately 126 days (GPOH cohort) or 80 days (rapid COJEC cohort), an end of treatment visit at the end of induction treatment and a post-discontinuation safety visit 30 days after the last administration of DB. Patients will enter the follow up phase after completing the induction treatment. We recommend to follow country/site protocol/guidelines for the management of the patients after the induction treatment (e.g. High Risk-NeuroBLastoma (HR-NBL)-2 study (EudraCT : 2019-001068-31).
There are two study periods:
The first period lasts until the last patient has completed the end of treatment visit. The analysis of these results will answer the primary endpoint of the study. The planned duration for each patient enrolled is approximately 5 months, and the total study duration is approximately 2 years.
The second period lasts until the last patient has completed the follow up. In this period, data for exploratory endpoints are collected. The plan is to report late toxicity (mainly related to the high-dose chemotherapy) when the last patient completed the end of study visit and in a further report the results of 3 and 5 years follow up.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Current use of a prohibited medication or requires any of these medications during the study:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Dinutuximab Beta will be administered at a fixed daily dose of 10 mg/m2 given as a 24-hour continuous infusion for a scheduled number of days within each treatment cycle of chemotherapy.
Biological: Dinutuximab beta · Drug: chemotherapy treatment called GPOH
Dinutuximab Beta will be administered at a fixed daily dose of 10 mg/m2 given as a 24-hour continuous infusion for a scheduled number of days within each treatment cycle of chemotherapy.
Biological: Dinutuximab beta · Drug: chemotherapy treatment called rapid COJEC
Combination of immunotherapy with standard chemotherapy
Also known as: Immunotherapy
chemotherapy treatment called GPOH
chemotherapy treatment called rapid COJEC
the incidence of dose limiting toxicities (DLTs) associated with the combination of Dinituximab Beta with GPOH chemotherapy regimen
Number of DLT's per dose level of Dinituximab Beta
Time frame: Within first 63 days of treatment
the incidence of dose limiting toxicities (DLTs) associated with the combination of Dinituximab Beta with rapid COJEC chemotherapy regimen
Number of DLT's per dose level of Dinituximab Beta
Time frame: Within first 50 days of treatment
overall response rate during after Dinituximab Beta with GPOH chemotherapy regimen
Tumor imaging
Time frame: 126 days
metastatic response rate after Dinituximab Beta with GPOH chemotherapy regimen
Tumor imaging
Time frame: 126 days
overall response rate during after Dinituximab Beta with rapid COJEC chemotherapy regimen
Tumor imaging
Time frame: 80 days
metastatic response rate after Dinituximab Beta with rapid COJEC chemotherapy regimen
Tumor imaging
Time frame: 80 days
event free survival (EFS) from the date of enrollment
exploratory endpoints
Time frame: 5 years
overall survival (OS) from the date of enrollment
exploratory endpoints
Time frame: 5 years
Plan to share: Yes — all IPD that underlie results in a publication (CSR)
Supporting information: Clinical study report
Time frame: Within 6 months from study end.
No publications or documents are linked to this record.
Started Jan 2025 (actual). Primary completion is estimated for Jul 2030, 65 months after the start.
Of 73 non-industry phase 1 interventional studies under Neuroblastoma, half reached primary completion within 89 months of starting (the median), counting those still running; a quarter within 65 and three quarters within 117. This study's planned 65 months is below that.
Counting every sponsor, half of 86 studies reached it within 83 months; a quarter within 60 and three quarters within 114.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Princess Maxima Center for Pediatric Oncology